nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0162	0.122	CbGbCtD
Bosutinib—ABCB1—Tacrolimus—atopic dermatitis	0.016	0.121	CbGbCtD
Bosutinib—ABCB1—Loratadine—atopic dermatitis	0.0117	0.0888	CbGbCtD
Bosutinib—ABCB1—Methylprednisolone—atopic dermatitis	0.0107	0.0813	CbGbCtD
Bosutinib—CYP3A4—Tacrolimus—atopic dermatitis	0.00961	0.0727	CbGbCtD
Bosutinib—CYP3A4—Loratadine—atopic dermatitis	0.00703	0.0532	CbGbCtD
Bosutinib—ABCB1—Betamethasone—atopic dermatitis	0.00698	0.0528	CbGbCtD
Bosutinib—ABCB1—Prednisolone—atopic dermatitis	0.00689	0.0521	CbGbCtD
Bosutinib—ABCB1—Hydrocortisone—atopic dermatitis	0.00653	0.0494	CbGbCtD
Bosutinib—ABCB1—Prednisone—atopic dermatitis	0.0065	0.0492	CbGbCtD
Bosutinib—CYP3A4—Methylprednisolone—atopic dermatitis	0.00643	0.0487	CbGbCtD
Bosutinib—PTK2—skin epidermis—atopic dermatitis	0.00502	0.0294	CbGeAlD
Bosutinib—CYP3A4—Triamcinolone—atopic dermatitis	0.00487	0.0369	CbGbCtD
Bosutinib—PKMYT1—neck—atopic dermatitis	0.00477	0.0279	CbGeAlD
Bosutinib—CDK2—neck—atopic dermatitis	0.00423	0.0248	CbGeAlD
Bosutinib—CYP3A4—Betamethasone—atopic dermatitis	0.00418	0.0317	CbGbCtD
Bosutinib—CYP3A4—Prednisolone—atopic dermatitis	0.00413	0.0312	CbGbCtD
Bosutinib—ABCB1—Dexamethasone—atopic dermatitis	0.00406	0.0307	CbGbCtD
Bosutinib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00391	0.0296	CbGbCtD
Bosutinib—CYP3A4—Prednisone—atopic dermatitis	0.0039	0.0295	CbGbCtD
Bosutinib—BMX—skin of body—atopic dermatitis	0.00301	0.0176	CbGeAlD
Bosutinib—MAP2K1—neck—atopic dermatitis	0.00281	0.0165	CbGeAlD
Bosutinib—CSNK1A1—neck—atopic dermatitis	0.00277	0.0163	CbGeAlD
Bosutinib—CLK1—neck—atopic dermatitis	0.00275	0.0161	CbGeAlD
Bosutinib—CDK2—skin of body—atopic dermatitis	0.00274	0.0161	CbGeAlD
Bosutinib—BMP2K—neck—atopic dermatitis	0.0027	0.0158	CbGeAlD
Bosutinib—CYP3A4—Dexamethasone—atopic dermatitis	0.00243	0.0184	CbGbCtD
Bosutinib—PLK2—skin of body—atopic dermatitis	0.00241	0.0142	CbGeAlD
Bosutinib—TBK1—neck—atopic dermatitis	0.0024	0.0141	CbGeAlD
Bosutinib—PTK2—neck—atopic dermatitis	0.0024	0.0141	CbGeAlD
Bosutinib—MAST1—head—atopic dermatitis	0.00238	0.014	CbGeAlD
Bosutinib—RPS6KB1—neck—atopic dermatitis	0.00231	0.0136	CbGeAlD
Bosutinib—STK24—skin of body—atopic dermatitis	0.00226	0.0132	CbGeAlD
Bosutinib—TYRO3—skin of body—atopic dermatitis	0.00218	0.0128	CbGeAlD
Bosutinib—TLK1—head—atopic dermatitis	0.00212	0.0124	CbGeAlD
Bosutinib—PRKCQ—head—atopic dermatitis	0.00209	0.0123	CbGeAlD
Bosutinib—SIK2—head—atopic dermatitis	0.00207	0.0121	CbGeAlD
Bosutinib—PKMYT1—head—atopic dermatitis	0.00201	0.0118	CbGeAlD
Bosutinib—CLK3—head—atopic dermatitis	0.00196	0.0115	CbGeAlD
Bosutinib—BMPR2—skin of body—atopic dermatitis	0.00196	0.0115	CbGeAlD
Bosutinib—PHKG1—head—atopic dermatitis	0.00192	0.0113	CbGeAlD
Bosutinib—EPHB2—head—atopic dermatitis	0.00192	0.0113	CbGeAlD
Bosutinib—SRMS—head—atopic dermatitis	0.00188	0.011	CbGeAlD
Bosutinib—TXK—head—atopic dermatitis	0.00186	0.0109	CbGeAlD
Bosutinib—EPHA8—head—atopic dermatitis	0.00184	0.0108	CbGeAlD
Bosutinib—MAP2K1—skin of body—atopic dermatitis	0.00182	0.0107	CbGeAlD
Bosutinib—STK35—skin of body—atopic dermatitis	0.00182	0.0107	CbGeAlD
Bosutinib—CSK—skin of body—atopic dermatitis	0.00181	0.0106	CbGeAlD
Bosutinib—SYK—head—atopic dermatitis	0.00181	0.0106	CbGeAlD
Bosutinib—CSNK1A1—skin of body—atopic dermatitis	0.00179	0.0105	CbGeAlD
Bosutinib—CDK2—head—atopic dermatitis	0.00179	0.0105	CbGeAlD
Bosutinib—STK26—head—atopic dermatitis	0.00177	0.0104	CbGeAlD
Bosutinib—DMPK—head—atopic dermatitis	0.0017	0.00995	CbGeAlD
Bosutinib—WEE1—head—atopic dermatitis	0.0017	0.00995	CbGeAlD
Bosutinib—CSNK1E—skin of body—atopic dermatitis	0.00166	0.00975	CbGeAlD
Bosutinib—SIK1—skin of body—atopic dermatitis	0.00164	0.00959	CbGeAlD
Bosutinib—STK25—head—atopic dermatitis	0.00162	0.0095	CbGeAlD
Bosutinib—EPHA3—head—atopic dermatitis	0.00161	0.00943	CbGeAlD
Bosutinib—ERBB3—skin of body—atopic dermatitis	0.0016	0.0094	CbGeAlD
Bosutinib—MAP2K2—skin of body—atopic dermatitis	0.0016	0.00938	CbGeAlD
Bosutinib—PLK2—head—atopic dermatitis	0.00158	0.00924	CbGeAlD
Bosutinib—SIK3—head—atopic dermatitis	0.00157	0.00917	CbGeAlD
Bosutinib—PTK2—skin of body—atopic dermatitis	0.00156	0.00912	CbGeAlD
Bosutinib—STK4—head—atopic dermatitis	0.00151	0.00883	CbGeAlD
Bosutinib—CAMK1D—head—atopic dermatitis	0.00149	0.00873	CbGeAlD
Bosutinib—AXL—skin of body—atopic dermatitis	0.00148	0.00869	CbGeAlD
Bosutinib—PDGFRB—neck—atopic dermatitis	0.00148	0.00868	CbGeAlD
Bosutinib—STK24—head—atopic dermatitis	0.00147	0.00863	CbGeAlD
Bosutinib—FER—head—atopic dermatitis	0.00142	0.00835	CbGeAlD
Bosutinib—ALK—head—atopic dermatitis	0.00142	0.00835	CbGeAlD
Bosutinib—TYRO3—head—atopic dermatitis	0.00142	0.00835	CbGeAlD
Bosutinib—EPHA5—head—atopic dermatitis	0.00142	0.00835	CbGeAlD
Bosutinib—LYN—head—atopic dermatitis	0.00142	0.0083	CbGeAlD
Bosutinib—MAP3K19—head—atopic dermatitis	0.0014	0.00818	CbGeAlD
Bosutinib—FYN—skin of body—atopic dermatitis	0.00139	0.00813	CbGeAlD
Bosutinib—TNK2—head—atopic dermatitis	0.00137	0.00802	CbGeAlD
Bosutinib—MAP3K3—skin of body—atopic dermatitis	0.00136	0.00794	CbGeAlD
Bosutinib—ERBB4—head—atopic dermatitis	0.00133	0.0078	CbGeAlD
Bosutinib—STK3—head—atopic dermatitis	0.00133	0.0078	CbGeAlD
Bosutinib—ROCK1—head—atopic dermatitis	0.00131	0.0077	CbGeAlD
Bosutinib—BMPR2—head—atopic dermatitis	0.00128	0.00748	CbGeAlD
Bosutinib—STK36—head—atopic dermatitis	0.00127	0.00742	CbGeAlD
Bosutinib—EPHB3—head—atopic dermatitis	0.00127	0.00742	CbGeAlD
Bosutinib—MERTK—head—atopic dermatitis	0.00125	0.00733	CbGeAlD
Bosutinib—MAP4K4—head—atopic dermatitis	0.00123	0.0072	CbGeAlD
Bosutinib—BCR—head—atopic dermatitis	0.00122	0.00715	CbGeAlD
Bosutinib—MAP3K12—head—atopic dermatitis	0.00121	0.0071	CbGeAlD
Bosutinib—SRC—skin of body—atopic dermatitis	0.0012	0.00706	CbGeAlD
Bosutinib—MAP2K1—head—atopic dermatitis	0.00119	0.00695	CbGeAlD
Bosutinib—STK35—head—atopic dermatitis	0.00119	0.00695	CbGeAlD
Bosutinib—CSK—head—atopic dermatitis	0.00118	0.00691	CbGeAlD
Bosutinib—CSNK1A1—head—atopic dermatitis	0.00117	0.00686	CbGeAlD
Bosutinib—CLK1—head—atopic dermatitis	0.00116	0.00682	CbGeAlD
Bosutinib—HCK—head—atopic dermatitis	0.00116	0.00682	CbGeAlD
Bosutinib—CAMK2G—head—atopic dermatitis	0.00114	0.00669	CbGeAlD
Bosutinib—BMP2K—head—atopic dermatitis	0.00114	0.00669	CbGeAlD
Bosutinib—LRRK2—head—atopic dermatitis	0.00113	0.00663	CbGeAlD
Bosutinib—PTK2B—head—atopic dermatitis	0.0011	0.00646	CbGeAlD
Bosutinib—CSNK1E—head—atopic dermatitis	0.00108	0.00636	CbGeAlD
Bosutinib—CSF1R—skin of body—atopic dermatitis	0.00108	0.00634	CbGeAlD
Bosutinib—SIK1—head—atopic dermatitis	0.00107	0.00626	CbGeAlD
Bosutinib—IRAK4—head—atopic dermatitis	0.00107	0.00626	CbGeAlD
Bosutinib—EPHA4—head—atopic dermatitis	0.00106	0.0062	CbGeAlD
Bosutinib—ERBB3—head—atopic dermatitis	0.00105	0.00614	CbGeAlD
Bosutinib—MAP2K2—head—atopic dermatitis	0.00104	0.00612	CbGeAlD
Bosutinib—ULK3—head—atopic dermatitis	0.00104	0.00612	CbGeAlD
Bosutinib—MAP3K2—head—atopic dermatitis	0.00104	0.00608	CbGeAlD
Bosutinib—TBK1—head—atopic dermatitis	0.00102	0.00595	CbGeAlD
Bosutinib—PTK2—head—atopic dermatitis	0.00102	0.00595	CbGeAlD
Bosutinib—RPS6KB1—head—atopic dermatitis	0.000977	0.00573	CbGeAlD
Bosutinib—FGR—head—atopic dermatitis	0.000971	0.00569	CbGeAlD
Bosutinib—AXL—head—atopic dermatitis	0.000967	0.00567	CbGeAlD
Bosutinib—PDGFRB—skin of body—atopic dermatitis	0.000959	0.00562	CbGeAlD
Bosutinib—EPHA2—head—atopic dermatitis	0.000907	0.00531	CbGeAlD
Bosutinib—FYN—head—atopic dermatitis	0.000905	0.0053	CbGeAlD
Bosutinib—MAP4K5—head—atopic dermatitis	0.000884	0.00518	CbGeAlD
Bosutinib—MAP3K3—head—atopic dermatitis	0.000884	0.00518	CbGeAlD
Bosutinib—ABL1—skin of body—atopic dermatitis	0.000855	0.00501	CbGeAlD
Bosutinib—CASK—Temsirolimus—Pimecrolimus—atopic dermatitis	0.000854	0.0835	CbGdCrCtD
Bosutinib—CASK—Temsirolimus—Tacrolimus—atopic dermatitis	0.000854	0.0835	CbGdCrCtD
Bosutinib—YES1—head—atopic dermatitis	0.000817	0.00479	CbGeAlD
Bosutinib—STK10—head—atopic dermatitis	0.000809	0.00474	CbGeAlD
Bosutinib—TAOK3—head—atopic dermatitis	0.000806	0.00473	CbGeAlD
Bosutinib—SRC—head—atopic dermatitis	0.000786	0.00461	CbGeAlD
Bosutinib—MAP2K5—head—atopic dermatitis	0.000723	0.00424	CbGeAlD
Bosutinib—CSF1R—head—atopic dermatitis	0.000705	0.00413	CbGeAlD
Bosutinib—PDGFRB—head—atopic dermatitis	0.000626	0.00367	CbGeAlD
Bosutinib—ABL1—head—atopic dermatitis	0.000558	0.00327	CbGeAlD
Bosutinib—CSK—Everolimus—Pimecrolimus—atopic dermatitis	0.000508	0.0496	CbGdCrCtD
Bosutinib—CSK—Sirolimus—Pimecrolimus—atopic dermatitis	0.000508	0.0496	CbGdCrCtD
Bosutinib—CSK—Sirolimus—Tacrolimus—atopic dermatitis	0.000508	0.0496	CbGdCrCtD
Bosutinib—CSK—Everolimus—Tacrolimus—atopic dermatitis	0.000508	0.0496	CbGdCrCtD
Bosutinib—CSK—Temsirolimus—Pimecrolimus—atopic dermatitis	0.000508	0.0496	CbGdCrCtD
Bosutinib—CSK—Temsirolimus—Tacrolimus—atopic dermatitis	0.000508	0.0496	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Desonide—atopic dermatitis	0.000461	0.045	CbGdCrCtD
Bosutinib—Upper respiratory tract infection—Hydrocortisone—atopic dermatitis	0.000402	0.00143	CcSEcCtD
Bosutinib—Diarrhoea—Loratadine—atopic dermatitis	0.000395	0.0014	CcSEcCtD
Bosutinib—Anaphylactic shock—Tacrolimus—atopic dermatitis	0.000394	0.0014	CcSEcCtD
Bosutinib—Oedema—Tacrolimus—atopic dermatitis	0.000394	0.0014	CcSEcCtD
Bosutinib—Infection—Tacrolimus—atopic dermatitis	0.000392	0.00139	CcSEcCtD
Bosutinib—Bronchitis—Triamcinolone—atopic dermatitis	0.000392	0.00139	CcSEcCtD
Bosutinib—Abdominal pain—Mometasone—atopic dermatitis	0.000392	0.00139	CcSEcCtD
Bosutinib—Body temperature increased—Mometasone—atopic dermatitis	0.000392	0.00139	CcSEcCtD
Bosutinib—Nervous system disorder—Tacrolimus—atopic dermatitis	0.000387	0.00137	CcSEcCtD
Bosutinib—Thrombocytopenia—Tacrolimus—atopic dermatitis	0.000386	0.00137	CcSEcCtD
Bosutinib—Infestation NOS—Hydrocortisone—atopic dermatitis	0.000386	0.00137	CcSEcCtD
Bosutinib—Infestation—Hydrocortisone—atopic dermatitis	0.000386	0.00137	CcSEcCtD
Bosutinib—Skin disorder—Tacrolimus—atopic dermatitis	0.000383	0.00136	CcSEcCtD
Bosutinib—Dizziness—Loratadine—atopic dermatitis	0.000382	0.00135	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Triamcinolone—atopic dermatitis	0.000379	0.00134	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Prednisone—atopic dermatitis	0.000372	0.00132	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Fluocinonide—atopic dermatitis	0.000369	0.036	CbGdCrCtD
Bosutinib—Pruritus—Fluocinolone Acetonide—atopic dermatitis	0.000367	0.0013	CcSEcCtD
Bosutinib—Vomiting—Loratadine—atopic dermatitis	0.000367	0.0013	CcSEcCtD
Bosutinib—Rash—Loratadine—atopic dermatitis	0.000364	0.00129	CcSEcCtD
Bosutinib—Dermatitis—Loratadine—atopic dermatitis	0.000364	0.00129	CcSEcCtD
Bosutinib—Infestation—Methylprednisolone—atopic dermatitis	0.000362	0.00129	CcSEcCtD
Bosutinib—Infestation NOS—Methylprednisolone—atopic dermatitis	0.000362	0.00129	CcSEcCtD
Bosutinib—Headache—Loratadine—atopic dermatitis	0.000362	0.00128	CcSEcCtD
Bosutinib—Face oedema—Prednisone—atopic dermatitis	0.00036	0.00128	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Tacrolimus—atopic dermatitis	0.000359	0.00127	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Fluocinolone Acetonide—atopic dermatitis	0.000359	0.035	CbGdCrCtD
Bosutinib—Asthenia—Mometasone—atopic dermatitis	0.000355	0.00126	CcSEcCtD
Bosutinib—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	0.000355	0.00126	CcSEcCtD
Bosutinib—Dyspnoea—Tacrolimus—atopic dermatitis	0.000352	0.00125	CcSEcCtD
Bosutinib—Pruritus—Mometasone—atopic dermatitis	0.000351	0.00124	CcSEcCtD
Bosutinib—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000343	0.00122	CcSEcCtD
Bosutinib—Nausea—Loratadine—atopic dermatitis	0.000343	0.00122	CcSEcCtD
Bosutinib—Decreased appetite—Tacrolimus—atopic dermatitis	0.000343	0.00122	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.00034	0.00121	CcSEcCtD
Bosutinib—Connective tissue disorder—Hydrocortisone—atopic dermatitis	0.00034	0.00121	CcSEcCtD
Bosutinib—Fatigue—Tacrolimus—atopic dermatitis	0.00034	0.00121	CcSEcCtD
Bosutinib—Diarrhoea—Mometasone—atopic dermatitis	0.000339	0.0012	CcSEcCtD
Bosutinib—Pain—Tacrolimus—atopic dermatitis	0.000337	0.0012	CcSEcCtD
Bosutinib—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.00033	0.00117	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Prednisone—atopic dermatitis	0.000328	0.00117	CcSEcCtD
Bosutinib—Rash—Fluocinolone Acetonide—atopic dermatitis	0.000327	0.00116	CcSEcCtD
Bosutinib—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	0.000327	0.00116	CcSEcCtD
Bosutinib—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000325	0.00115	CcSEcCtD
Bosutinib—Feeling abnormal—Tacrolimus—atopic dermatitis	0.000325	0.00115	CcSEcCtD
Bosutinib—Gastrointestinal pain—Tacrolimus—atopic dermatitis	0.000322	0.00114	CcSEcCtD
Bosutinib—Connective tissue disorder—Methylprednisolone—atopic dermatitis	0.00032	0.00113	CcSEcCtD
Bosutinib—Vomiting—Mometasone—atopic dermatitis	0.000315	0.00112	CcSEcCtD
Bosutinib—Urticaria—Tacrolimus—atopic dermatitis	0.000313	0.00111	CcSEcCtD
Bosutinib—Immune system disorder—Hydrocortisone—atopic dermatitis	0.000313	0.00111	CcSEcCtD
Bosutinib—Rash—Mometasone—atopic dermatitis	0.000312	0.00111	CcSEcCtD
Bosutinib—Dermatitis—Mometasone—atopic dermatitis	0.000312	0.00111	CcSEcCtD
Bosutinib—Body temperature increased—Tacrolimus—atopic dermatitis	0.000312	0.00111	CcSEcCtD
Bosutinib—Abdominal pain—Tacrolimus—atopic dermatitis	0.000312	0.00111	CcSEcCtD
Bosutinib—Headache—Mometasone—atopic dermatitis	0.00031	0.0011	CcSEcCtD
Bosutinib—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000308	0.00109	CcSEcCtD
Bosutinib—Cardiac disorder—Methylprednisolone—atopic dermatitis	0.000302	0.00107	CcSEcCtD
Bosutinib—Malnutrition—Hydrocortisone—atopic dermatitis	0.000301	0.00107	CcSEcCtD
Bosutinib—Neutropenia—Prednisone—atopic dermatitis	0.000301	0.00107	CcSEcCtD
Bosutinib—Nausea—Mometasone—atopic dermatitis	0.000294	0.00104	CcSEcCtD
Bosutinib—Immune system disorder—Methylprednisolone—atopic dermatitis	0.000294	0.00104	CcSEcCtD
Bosutinib—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000293	0.00104	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisolone—atopic dermatitis	0.000286	0.00102	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Mometasone—atopic dermatitis	0.000286	0.0279	CbGdCrCtD
Bosutinib—Malnutrition—Methylprednisolone—atopic dermatitis	0.000283	0.001	CcSEcCtD
Bosutinib—Asthenia—Tacrolimus—atopic dermatitis	0.000283	0.001	CcSEcCtD
Bosutinib—Ill-defined disorder—Hydrocortisone—atopic dermatitis	0.00028	0.000992	CcSEcCtD
Bosutinib—Pruritus—Tacrolimus—atopic dermatitis	0.000279	0.00099	CcSEcCtD
Bosutinib—Malaise—Prednisolone—atopic dermatitis	0.000278	0.000988	CcSEcCtD
Bosutinib—Dysgeusia—Triamcinolone—atopic dermatitis	0.000278	0.000986	CcSEcCtD
Bosutinib—Back pain—Triamcinolone—atopic dermatitis	0.000275	0.000974	CcSEcCtD
Bosutinib—PTK2B—Carbinoxamine—Diphenhydramine—atopic dermatitis	0.000274	0.0267	CbGdCrCtD
Bosutinib—Malaise—Hydrocortisone—atopic dermatitis	0.000272	0.000965	CcSEcCtD
Bosutinib—Diarrhoea—Tacrolimus—atopic dermatitis	0.00027	0.000957	CcSEcCtD
Bosutinib—Ill-defined disorder—Triamcinolone—atopic dermatitis	0.000263	0.000934	CcSEcCtD
Bosutinib—Ill-defined disorder—Methylprednisolone—atopic dermatitis	0.000263	0.000932	CcSEcCtD
Bosutinib—Dizziness—Tacrolimus—atopic dermatitis	0.000261	0.000925	CcSEcCtD
Bosutinib—Discomfort—Prednisolone—atopic dermatitis	0.00026	0.000921	CcSEcCtD
Bosutinib—Myalgia—Hydrocortisone—atopic dermatitis	0.000257	0.000911	CcSEcCtD
Bosutinib—Malaise—Triamcinolone—atopic dermatitis	0.000256	0.000908	CcSEcCtD
Bosutinib—Malaise—Methylprednisolone—atopic dermatitis	0.000255	0.000906	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000255	0.000904	CcSEcCtD
Bosutinib—Discomfort—Hydrocortisone—atopic dermatitis	0.000254	0.0009	CcSEcCtD
Bosutinib—Connective tissue disorder—Prednisone—atopic dermatitis	0.000253	0.000898	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisolone—atopic dermatitis	0.000252	0.000894	CcSEcCtD
Bosutinib—Oedema—Prednisolone—atopic dermatitis	0.000252	0.000894	CcSEcCtD
Bosutinib—Vomiting—Tacrolimus—atopic dermatitis	0.000251	0.00089	CcSEcCtD
Bosutinib—Rash—Tacrolimus—atopic dermatitis	0.000249	0.000882	CcSEcCtD
Bosutinib—Dermatitis—Tacrolimus—atopic dermatitis	0.000248	0.000882	CcSEcCtD
Bosutinib—Cough—Triamcinolone—atopic dermatitis	0.000248	0.000879	CcSEcCtD
Bosutinib—Headache—Tacrolimus—atopic dermatitis	0.000247	0.000877	CcSEcCtD
Bosutinib—Anaphylactic shock—Hydrocortisone—atopic dermatitis	0.000246	0.000873	CcSEcCtD
Bosutinib—Oedema—Hydrocortisone—atopic dermatitis	0.000246	0.000873	CcSEcCtD
Bosutinib—Infection—Hydrocortisone—atopic dermatitis	0.000244	0.000867	CcSEcCtD
Bosutinib—Myalgia—Triamcinolone—atopic dermatitis	0.000242	0.000857	CcSEcCtD
Bosutinib—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000241	0.000856	CcSEcCtD
Bosutinib—Arthralgia—Methylprednisolone—atopic dermatitis	0.000241	0.000856	CcSEcCtD
Bosutinib—Myalgia—Methylprednisolone—atopic dermatitis	0.000241	0.000856	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000239	0.00085	CcSEcCtD
Bosutinib—Skin disorder—Hydrocortisone—atopic dermatitis	0.000239	0.000848	CcSEcCtD
Bosutinib—Ill-defined disorder—Dexamethasone—atopic dermatitis	0.000239	0.000848	CcSEcCtD
Bosutinib—Ill-defined disorder—Betamethasone—atopic dermatitis	0.000239	0.000848	CcSEcCtD
Bosutinib—Discomfort—Triamcinolone—atopic dermatitis	0.000239	0.000847	CcSEcCtD
Bosutinib—Discomfort—Methylprednisolone—atopic dermatitis	0.000238	0.000845	CcSEcCtD
Bosutinib—Nausea—Tacrolimus—atopic dermatitis	0.000234	0.000831	CcSEcCtD
Bosutinib—Immune system disorder—Prednisone—atopic dermatitis	0.000233	0.000826	CcSEcCtD
Bosutinib—Malaise—Dexamethasone—atopic dermatitis	0.000232	0.000824	CcSEcCtD
Bosutinib—Malaise—Betamethasone—atopic dermatitis	0.000232	0.000824	CcSEcCtD
Bosutinib—Anaphylactic shock—Triamcinolone—atopic dermatitis	0.000232	0.000822	CcSEcCtD
Bosutinib—Oedema—Triamcinolone—atopic dermatitis	0.000232	0.000822	CcSEcCtD
Bosutinib—Anaphylactic shock—Methylprednisolone—atopic dermatitis	0.000231	0.00082	CcSEcCtD
Bosutinib—Infection—Triamcinolone—atopic dermatitis	0.00023	0.000817	CcSEcCtD
Bosutinib—Infection—Methylprednisolone—atopic dermatitis	0.00023	0.000815	CcSEcCtD
Bosutinib—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000227	0.000804	CcSEcCtD
Bosutinib—Skin disorder—Methylprednisolone—atopic dermatitis	0.000224	0.000797	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—atopic dermatitis	0.000224	0.000796	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000224	0.000795	CcSEcCtD
Bosutinib—PLK2—Levonorgestrel—Hydrocortisone—atopic dermatitis	0.000223	0.0218	CbGdCrCtD
Bosutinib—Myalgia—Betamethasone—atopic dermatitis	0.000219	0.000778	CcSEcCtD
Bosutinib—Myalgia—Dexamethasone—atopic dermatitis	0.000219	0.000778	CcSEcCtD
Bosutinib—Discomfort—Betamethasone—atopic dermatitis	0.000217	0.000769	CcSEcCtD
Bosutinib—Discomfort—Dexamethasone—atopic dermatitis	0.000217	0.000769	CcSEcCtD
Bosutinib—Pain—Prednisolone—atopic dermatitis	0.000215	0.000764	CcSEcCtD
Bosutinib—MAP4K4—Testosterone Propionate—Hydrocortisone—atopic dermatitis	0.000215	0.021	CbGdCrCtD
Bosutinib—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000214	0.000759	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000212	0.000754	CcSEcCtD
Bosutinib—Fatigue—Hydrocortisone—atopic dermatitis	0.000212	0.000753	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.000211	0.000749	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.000211	0.000747	CcSEcCtD
Bosutinib—Pain—Hydrocortisone—atopic dermatitis	0.00021	0.000747	CcSEcCtD
Bosutinib—Oedema—Betamethasone—atopic dermatitis	0.00021	0.000746	CcSEcCtD
Bosutinib—Oedema—Dexamethasone—atopic dermatitis	0.00021	0.000746	CcSEcCtD
Bosutinib—Anaphylactic shock—Dexamethasone—atopic dermatitis	0.00021	0.000746	CcSEcCtD
Bosutinib—Anaphylactic shock—Betamethasone—atopic dermatitis	0.00021	0.000746	CcSEcCtD
Bosutinib—Infection—Dexamethasone—atopic dermatitis	0.000209	0.000741	CcSEcCtD
Bosutinib—Infection—Betamethasone—atopic dermatitis	0.000209	0.000741	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisone—atopic dermatitis	0.000208	0.000738	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisolone—atopic dermatitis	0.000208	0.000737	CcSEcCtD
Bosutinib—Anaemia—Prednisone—atopic dermatitis	0.000207	0.000736	CcSEcCtD
Bosutinib—Dyspnoea—Triamcinolone—atopic dermatitis	0.000207	0.000733	CcSEcCtD
Bosutinib—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000206	0.000731	CcSEcCtD
Bosutinib—Nervous system disorder—Betamethasone—atopic dermatitis	0.000206	0.000731	CcSEcCtD
Bosutinib—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.000206	0.00073	CcSEcCtD
Bosutinib—Thrombocytopenia—Betamethasone—atopic dermatitis	0.000206	0.00073	CcSEcCtD
Bosutinib—Feeling abnormal—Hydrocortisone—atopic dermatitis	0.000203	0.000719	CcSEcCtD
Bosutinib—Malaise—Prednisone—atopic dermatitis	0.000202	0.000718	CcSEcCtD
Bosutinib—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000201	0.000714	CcSEcCtD
Bosutinib—Urticaria—Prednisolone—atopic dermatitis	0.0002	0.00071	CcSEcCtD
Bosutinib—Fatigue—Triamcinolone—atopic dermatitis	0.0002	0.000709	CcSEcCtD
Bosutinib—Fatigue—Methylprednisolone—atopic dermatitis	0.000199	0.000707	CcSEcCtD
Bosutinib—Pain—Triamcinolone—atopic dermatitis	0.000198	0.000703	CcSEcCtD
Bosutinib—Urticaria—Hydrocortisone—atopic dermatitis	0.000195	0.000694	CcSEcCtD
Bosutinib—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000194	0.00069	CcSEcCtD
Bosutinib—Abdominal pain—Hydrocortisone—atopic dermatitis	0.000194	0.00069	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	0.000191	0.00068	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	0.000191	0.00068	CcSEcCtD
Bosutinib—Myalgia—Prednisone—atopic dermatitis	0.000191	0.000678	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—atopic dermatitis	0.000191	0.000678	CcSEcCtD
Bosutinib—Feeling abnormal—Triamcinolone—atopic dermatitis	0.000191	0.000677	CcSEcCtD
Bosutinib—Feeling abnormal—Methylprednisolone—atopic dermatitis	0.00019	0.000676	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.00019	0.000673	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	0.000189	0.000671	CcSEcCtD
Bosutinib—Discomfort—Prednisone—atopic dermatitis	0.000189	0.000669	CcSEcCtD
Bosutinib—Urticaria—Triamcinolone—atopic dermatitis	0.000184	0.000653	CcSEcCtD
Bosutinib—Urticaria—Methylprednisolone—atopic dermatitis	0.000184	0.000652	CcSEcCtD
Bosutinib—Body temperature increased—Triamcinolone—atopic dermatitis	0.000183	0.00065	CcSEcCtD
Bosutinib—Oedema—Prednisone—atopic dermatitis	0.000183	0.00065	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—atopic dermatitis	0.000183	0.00065	CcSEcCtD
Bosutinib—Abdominal pain—Methylprednisolone—atopic dermatitis	0.000183	0.000648	CcSEcCtD
Bosutinib—Decreased appetite—Betamethasone—atopic dermatitis	0.000183	0.000648	CcSEcCtD
Bosutinib—Decreased appetite—Dexamethasone—atopic dermatitis	0.000183	0.000648	CcSEcCtD
Bosutinib—Infection—Prednisone—atopic dermatitis	0.000182	0.000645	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000181	0.000644	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000181	0.000644	CcSEcCtD
Bosutinib—Fatigue—Betamethasone—atopic dermatitis	0.000181	0.000643	CcSEcCtD
Bosutinib—Fatigue—Dexamethasone—atopic dermatitis	0.000181	0.000643	CcSEcCtD
Bosutinib—Pain—Betamethasone—atopic dermatitis	0.00018	0.000638	CcSEcCtD
Bosutinib—Pain—Dexamethasone—atopic dermatitis	0.00018	0.000638	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—atopic dermatitis	0.000179	0.000637	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—atopic dermatitis	0.000178	0.000631	CcSEcCtD
Bosutinib—Asthenia—Hydrocortisone—atopic dermatitis	0.000176	0.000626	CcSEcCtD
Bosutinib—Pruritus—Hydrocortisone—atopic dermatitis	0.000174	0.000618	CcSEcCtD
Bosutinib—ABCB1—head—atopic dermatitis	0.000173	0.00102	CbGeAlD
Bosutinib—Feeling abnormal—Dexamethasone—atopic dermatitis	0.000173	0.000615	CcSEcCtD
Bosutinib—Feeling abnormal—Betamethasone—atopic dermatitis	0.000173	0.000615	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dexamethasone—atopic dermatitis	0.000172	0.00061	CcSEcCtD
Bosutinib—Gastrointestinal pain—Betamethasone—atopic dermatitis	0.000172	0.00061	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Methylprednisolone—atopic dermatitis	0.000171	0.0167	CbGdCrCtD
Bosutinib—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000168	0.000597	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Betamethasone—atopic dermatitis	0.000168	0.0164	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Dexamethasone—atopic dermatitis	0.000168	0.0164	CbGdCrCtD
Bosutinib—Urticaria—Dexamethasone—atopic dermatitis	0.000167	0.000593	CcSEcCtD
Bosutinib—Urticaria—Betamethasone—atopic dermatitis	0.000167	0.000593	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—atopic dermatitis	0.000167	0.000592	CcSEcCtD
Bosutinib—Dizziness—Prednisolone—atopic dermatitis	0.000167	0.000591	CcSEcCtD
Bosutinib—Asthenia—Triamcinolone—atopic dermatitis	0.000166	0.00059	CcSEcCtD
Bosutinib—Abdominal pain—Betamethasone—atopic dermatitis	0.000166	0.00059	CcSEcCtD
Bosutinib—Body temperature increased—Dexamethasone—atopic dermatitis	0.000166	0.00059	CcSEcCtD
Bosutinib—Abdominal pain—Dexamethasone—atopic dermatitis	0.000166	0.00059	CcSEcCtD
Bosutinib—Body temperature increased—Betamethasone—atopic dermatitis	0.000166	0.00059	CcSEcCtD
Bosutinib—Asthenia—Methylprednisolone—atopic dermatitis	0.000166	0.000588	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Triamcinolone—atopic dermatitis	0.000164	0.0161	CbGdCrCtD
Bosutinib—Pruritus—Triamcinolone—atopic dermatitis	0.000164	0.000582	CcSEcCtD
Bosutinib—Pruritus—Methylprednisolone—atopic dermatitis	0.000164	0.00058	CcSEcCtD
Bosutinib—Dizziness—Hydrocortisone—atopic dermatitis	0.000163	0.000577	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Desonide—atopic dermatitis	0.000159	0.0156	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Desonide—atopic dermatitis	0.000159	0.0156	CbGdCrCtD
Bosutinib—Decreased appetite—Prednisone—atopic dermatitis	0.000159	0.000565	CcSEcCtD
Bosutinib—Rash—Prednisolone—atopic dermatitis	0.000159	0.000564	CcSEcCtD
Bosutinib—Dermatitis—Prednisolone—atopic dermatitis	0.000159	0.000563	CcSEcCtD
Bosutinib—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000158	0.000561	CcSEcCtD
Bosutinib—Fatigue—Prednisone—atopic dermatitis	0.000158	0.00056	CcSEcCtD
Bosutinib—Headache—Prednisolone—atopic dermatitis	0.000158	0.00056	CcSEcCtD
Bosutinib—Vomiting—Hydrocortisone—atopic dermatitis	0.000156	0.000555	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Prednisone—atopic dermatitis	0.000156	0.0152	CbGdCrCtD
Bosutinib—Rash—Hydrocortisone—atopic dermatitis	0.000155	0.00055	CcSEcCtD
Bosutinib—Dermatitis—Hydrocortisone—atopic dermatitis	0.000155	0.00055	CcSEcCtD
Bosutinib—Headache—Hydrocortisone—atopic dermatitis	0.000154	0.000547	CcSEcCtD
Bosutinib—Dizziness—Triamcinolone—atopic dermatitis	0.000153	0.000544	CcSEcCtD
Bosutinib—Dizziness—Methylprednisolone—atopic dermatitis	0.000153	0.000542	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Prednisolone—atopic dermatitis	0.000152	0.0149	CbGdCrCtD
Bosutinib—Feeling abnormal—Prednisone—atopic dermatitis	0.000151	0.000535	CcSEcCtD
Bosutinib—Asthenia—Betamethasone—atopic dermatitis	0.000151	0.000535	CcSEcCtD
Bosutinib—Asthenia—Dexamethasone—atopic dermatitis	0.000151	0.000535	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—atopic dermatitis	0.00015	0.000531	CcSEcCtD
Bosutinib—Nausea—Prednisolone—atopic dermatitis	0.00015	0.000531	CcSEcCtD
Bosutinib—Pruritus—Dexamethasone—atopic dermatitis	0.000149	0.000528	CcSEcCtD
Bosutinib—Pruritus—Betamethasone—atopic dermatitis	0.000149	0.000528	CcSEcCtD
Bosutinib—Vomiting—Triamcinolone—atopic dermatitis	0.000147	0.000523	CcSEcCtD
Bosutinib—Vomiting—Methylprednisolone—atopic dermatitis	0.000147	0.000521	CcSEcCtD
Bosutinib—Nausea—Hydrocortisone—atopic dermatitis	0.000146	0.000519	CcSEcCtD
Bosutinib—Rash—Triamcinolone—atopic dermatitis	0.000146	0.000518	CcSEcCtD
Bosutinib—Dermatitis—Triamcinolone—atopic dermatitis	0.000146	0.000518	CcSEcCtD
Bosutinib—Rash—Methylprednisolone—atopic dermatitis	0.000146	0.000517	CcSEcCtD
Bosutinib—Dermatitis—Methylprednisolone—atopic dermatitis	0.000146	0.000517	CcSEcCtD
Bosutinib—Urticaria—Prednisone—atopic dermatitis	0.000145	0.000516	CcSEcCtD
Bosutinib—Headache—Triamcinolone—atopic dermatitis	0.000145	0.000515	CcSEcCtD
Bosutinib—Headache—Methylprednisolone—atopic dermatitis	0.000145	0.000514	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—atopic dermatitis	0.000145	0.000513	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—atopic dermatitis	0.000145	0.000513	CcSEcCtD
Bosutinib—Diarrhoea—Betamethasone—atopic dermatitis	0.000144	0.00051	CcSEcCtD
Bosutinib—Diarrhoea—Dexamethasone—atopic dermatitis	0.000144	0.00051	CcSEcCtD
Bosutinib—Dizziness—Dexamethasone—atopic dermatitis	0.000139	0.000493	CcSEcCtD
Bosutinib—Dizziness—Betamethasone—atopic dermatitis	0.000139	0.000493	CcSEcCtD
Bosutinib—Nausea—Triamcinolone—atopic dermatitis	0.000138	0.000488	CcSEcCtD
Bosutinib—Nausea—Methylprednisolone—atopic dermatitis	0.000137	0.000487	CcSEcCtD
Bosutinib—Vomiting—Dexamethasone—atopic dermatitis	0.000134	0.000474	CcSEcCtD
Bosutinib—Vomiting—Betamethasone—atopic dermatitis	0.000134	0.000474	CcSEcCtD
Bosutinib—Rash—Dexamethasone—atopic dermatitis	0.000133	0.00047	CcSEcCtD
Bosutinib—Rash—Betamethasone—atopic dermatitis	0.000133	0.00047	CcSEcCtD
Bosutinib—Dermatitis—Betamethasone—atopic dermatitis	0.000132	0.00047	CcSEcCtD
Bosutinib—Dermatitis—Dexamethasone—atopic dermatitis	0.000132	0.00047	CcSEcCtD
Bosutinib—Headache—Dexamethasone—atopic dermatitis	0.000132	0.000467	CcSEcCtD
Bosutinib—Headache—Betamethasone—atopic dermatitis	0.000132	0.000467	CcSEcCtD
Bosutinib—Asthenia—Prednisone—atopic dermatitis	0.000131	0.000466	CcSEcCtD
Bosutinib—Pruritus—Prednisone—atopic dermatitis	0.000129	0.00046	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Fluocinonide—atopic dermatitis	0.000128	0.0125	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Fluocinonide—atopic dermatitis	0.000128	0.0125	CbGdCrCtD
Bosutinib—Diarrhoea—Prednisone—atopic dermatitis	0.000125	0.000444	CcSEcCtD
Bosutinib—Nausea—Betamethasone—atopic dermatitis	0.000125	0.000443	CcSEcCtD
Bosutinib—Nausea—Dexamethasone—atopic dermatitis	0.000125	0.000443	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Fluocinolone Acetonide—atopic dermatitis	0.000124	0.0121	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Fluocinolone Acetonide—atopic dermatitis	0.000124	0.0121	CbGdCrCtD
Bosutinib—Dizziness—Prednisone—atopic dermatitis	0.000121	0.00043	CcSEcCtD
Bosutinib—Vomiting—Prednisone—atopic dermatitis	0.000116	0.000413	CcSEcCtD
Bosutinib—Rash—Prednisone—atopic dermatitis	0.000115	0.00041	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—atopic dermatitis	0.000115	0.000409	CcSEcCtD
Bosutinib—Headache—Prednisone—atopic dermatitis	0.000115	0.000407	CcSEcCtD
Bosutinib—Nausea—Prednisone—atopic dermatitis	0.000109	0.000386	CcSEcCtD
Bosutinib—PKMYT1—Danazol—Hydrocortisone—atopic dermatitis	0.000103	0.01	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Mometasone—atopic dermatitis	9.89e-05	0.00966	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Mometasone—atopic dermatitis	9.89e-05	0.00966	CbGdCrCtD
Bosutinib—CSNK1E—Danazol—Hydrocortisone—atopic dermatitis	9.8e-05	0.00958	CbGdCrCtD
Bosutinib—PKMYT1—Danazol—Prednisone—atopic dermatitis	8.85e-05	0.00864	CbGdCrCtD
Bosutinib—CSNK1E—Danazol—Prednisone—atopic dermatitis	8.44e-05	0.00825	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Hydrocortisone—atopic dermatitis	6.26e-05	0.00611	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Hydrocortisone—atopic dermatitis	6.26e-05	0.00611	CbGdCrCtD
Bosutinib—CHEK2—Testosterone Propionate—Hydrocortisone—atopic dermatitis	6.04e-05	0.0059	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Methylprednisolone—atopic dermatitis	5.9e-05	0.00577	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Methylprednisolone—atopic dermatitis	5.9e-05	0.00577	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Betamethasone—atopic dermatitis	5.81e-05	0.00568	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Dexamethasone—atopic dermatitis	5.81e-05	0.00568	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Triamcinolone—atopic dermatitis	5.68e-05	0.00555	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Triamcinolone—atopic dermatitis	5.68e-05	0.00555	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—atopic dermatitis	5.39e-05	0.00526	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—atopic dermatitis	5.39e-05	0.00526	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisolone—atopic dermatitis	5.26e-05	0.00514	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisolone—atopic dermatitis	5.26e-05	0.00514	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Hydrocortisone—atopic dermatitis	5.02e-05	0.0049	CbGdCrCtD
Bosutinib—CHEK2—Norethindrone—Hydrocortisone—atopic dermatitis	4.52e-05	0.00442	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Prednisone—atopic dermatitis	4.32e-05	0.00422	CbGdCrCtD
Bosutinib—CHEK2—Levonorgestrel—Hydrocortisone—atopic dermatitis	3.6e-05	0.00351	CbGdCrCtD
Bosutinib—PTK2—Immune System—MAPK8—atopic dermatitis	7.18e-06	1.77e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NFKBIA—atopic dermatitis	7.16e-06	1.77e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCL5—atopic dermatitis	7.12e-06	1.76e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—IL6—atopic dermatitis	7.11e-06	1.76e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—MAPK8—atopic dermatitis	7.08e-06	1.75e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL5—atopic dermatitis	7.04e-06	1.74e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL10—atopic dermatitis	7.04e-06	1.74e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCL5—atopic dermatitis	7.01e-06	1.73e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCL5—atopic dermatitis	6.98e-06	1.72e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—IL6—atopic dermatitis	6.95e-06	1.71e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—IL6—atopic dermatitis	6.93e-06	1.71e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NFKBIA—atopic dermatitis	6.92e-06	1.71e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—TNF—atopic dermatitis	6.91e-06	1.7e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NGF—atopic dermatitis	6.9e-06	1.7e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—NFKBIA—atopic dermatitis	6.9e-06	1.7e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL1B—atopic dermatitis	6.89e-06	1.7e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—CXCL8—atopic dermatitis	6.87e-06	1.7e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL2—atopic dermatitis	6.87e-06	1.69e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—IL6—atopic dermatitis	6.86e-06	1.69e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MAPK8—atopic dermatitis	6.84e-06	1.69e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL10—atopic dermatitis	6.78e-06	1.67e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—IL6—atopic dermatitis	6.76e-06	1.67e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IFNG—atopic dermatitis	6.75e-06	1.67e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	6.74e-06	1.66e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NGF—atopic dermatitis	6.74e-06	1.66e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—CXCL8—atopic dermatitis	6.72e-06	1.66e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCR5—atopic dermatitis	6.72e-06	1.66e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—MAPK8—atopic dermatitis	6.71e-06	1.66e-05	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—IL6—atopic dermatitis	6.66e-06	1.64e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—CCR5—atopic dermatitis	6.65e-06	1.64e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—CXCL8—atopic dermatitis	6.63e-06	1.64e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NGF—atopic dermatitis	6.6e-06	1.63e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IFNG—atopic dermatitis	6.59e-06	1.63e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—MAPK8—atopic dermatitis	6.58e-06	1.62e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL2—atopic dermatitis	6.57e-06	1.62e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCR5—atopic dermatitis	6.55e-06	1.62e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—IL6—atopic dermatitis	6.55e-06	1.62e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD4—atopic dermatitis	6.52e-06	1.61e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—IL6—atopic dermatitis	6.52e-06	1.61e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NFKBIA—atopic dermatitis	6.52e-06	1.61e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NGF—atopic dermatitis	6.49e-06	1.6e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—IL6—atopic dermatitis	6.48e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NGF—atopic dermatitis	6.46e-06	1.59e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IL6—atopic dermatitis	6.46e-06	1.59e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CASP8—atopic dermatitis	6.46e-06	1.59e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IFNG—atopic dermatitis	6.45e-06	1.59e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—IL6—atopic dermatitis	6.45e-06	1.59e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—CXCL8—atopic dermatitis	6.43e-06	1.59e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL2—atopic dermatitis	6.43e-06	1.59e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IFNG—atopic dermatitis	6.42e-06	1.59e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCR5—atopic dermatitis	6.42e-06	1.58e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—IL6—atopic dermatitis	6.42e-06	1.58e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—CXCL8—atopic dermatitis	6.38e-06	1.58e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD4—atopic dermatitis	6.37e-06	1.57e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IFNG—atopic dermatitis	6.35e-06	1.57e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL2—atopic dermatitis	6.33e-06	1.56e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—MAPK8—atopic dermatitis	6.32e-06	1.56e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IFNG—atopic dermatitis	6.32e-06	1.56e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCR5—atopic dermatitis	6.32e-06	1.56e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCR5—atopic dermatitis	6.28e-06	1.55e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—IL6—atopic dermatitis	6.24e-06	1.54e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD4—atopic dermatitis	6.23e-06	1.54e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CASP8—atopic dermatitis	6.22e-06	1.54e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD4—atopic dermatitis	6.2e-06	1.53e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—IL6—atopic dermatitis	6.2e-06	1.53e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CXCL8—atopic dermatitis	6.15e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CXCL8—atopic dermatitis	6.15e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL2—atopic dermatitis	6.15e-06	1.52e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD4—atopic dermatitis	6.14e-06	1.51e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—NFKBIA—atopic dermatitis	6.11e-06	1.51e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD4—atopic dermatitis	6.1e-06	1.51e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL2—atopic dermatitis	6.1e-06	1.51e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—IL6—atopic dermatitis	6.07e-06	1.5e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCL5—atopic dermatitis	6.06e-06	1.5e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—IL6—atopic dermatitis	6.06e-06	1.49e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL1B—atopic dermatitis	6.03e-06	1.49e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—CD4—atopic dermatitis	6.02e-06	1.49e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL10—atopic dermatitis	6e-06	1.48e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL2—atopic dermatitis	6e-06	1.48e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GLB1—atopic dermatitis	6e-06	1.48e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CXCL8—atopic dermatitis	5.93e-06	1.46e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MAPK8—atopic dermatitis	5.91e-06	1.46e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—IL6—atopic dermatitis	5.91e-06	1.46e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TNF—atopic dermatitis	5.89e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL1B—atopic dermatitis	5.88e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—CD4—atopic dermatitis	5.88e-06	1.45e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL2—atopic dermatitis	5.88e-06	1.45e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL2—atopic dermatitis	5.88e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL2—atopic dermatitis	5.86e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IL6—atopic dermatitis	5.84e-06	1.44e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL5—atopic dermatitis	5.84e-06	1.44e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MAPK8—atopic dermatitis	5.83e-06	1.44e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—IL6—atopic dermatitis	5.79e-06	1.43e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IL6—atopic dermatitis	5.76e-06	1.42e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL6—atopic dermatitis	5.76e-06	1.42e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL1B—atopic dermatitis	5.76e-06	1.42e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADSL—atopic dermatitis	5.75e-06	1.42e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL2—atopic dermatitis	5.73e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL1B—atopic dermatitis	5.73e-06	1.41e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—IL6—atopic dermatitis	5.73e-06	1.41e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL2—atopic dermatitis	5.71e-06	1.41e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—atopic dermatitis	5.7e-06	1.41e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NFKBIA—atopic dermatitis	5.69e-06	1.41e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1B—atopic dermatitis	5.67e-06	1.4e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—atopic dermatitis	5.67e-06	1.4e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—CD4—atopic dermatitis	5.67e-06	1.4e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL2—atopic dermatitis	5.66e-06	1.4e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL2—atopic dermatitis	5.65e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1B—atopic dermatitis	5.64e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CD4—atopic dermatitis	5.64e-06	1.39e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—atopic dermatitis	5.62e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL2—atopic dermatitis	5.62e-06	1.39e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MAPK8—atopic dermatitis	5.61e-06	1.39e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NGF—atopic dermatitis	5.61e-06	1.38e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—atopic dermatitis	5.6e-06	1.38e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—CXCL8—atopic dermatitis	5.59e-06	1.38e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—atopic dermatitis	5.57e-06	1.38e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NFKBIA—atopic dermatitis	5.56e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—MAPK8—atopic dermatitis	5.52e-06	1.36e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—atopic dermatitis	5.51e-06	1.36e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CASP8—atopic dermatitis	5.51e-06	1.36e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IFNG—atopic dermatitis	5.49e-06	1.35e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCR5—atopic dermatitis	5.46e-06	1.35e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NFKBIA—atopic dermatitis	5.44e-06	1.34e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MAPK8—atopic dermatitis	5.41e-06	1.33e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MAPK8—atopic dermatitis	5.41e-06	1.33e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—atopic dermatitis	5.41e-06	1.33e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—atopic dermatitis	5.41e-06	1.33e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NGF—atopic dermatitis	5.41e-06	1.33e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—atopic dermatitis	5.39e-06	1.33e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—MAPK8—atopic dermatitis	5.39e-06	1.33e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NFKBIA—atopic dermatitis	5.36e-06	1.32e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL2—atopic dermatitis	5.34e-06	1.32e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NFKBIA—atopic dermatitis	5.33e-06	1.31e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD4—atopic dermatitis	5.3e-06	1.31e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IFNG—atopic dermatitis	5.29e-06	1.31e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—MAPK8—atopic dermatitis	5.28e-06	1.3e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CXCL8—atopic dermatitis	5.28e-06	1.3e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCR5—atopic dermatitis	5.26e-06	1.3e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—MAPK8—atopic dermatitis	5.25e-06	1.3e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—atopic dermatitis	5.22e-06	1.29e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MAPK8—atopic dermatitis	5.21e-06	1.29e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CXCL8—atopic dermatitis	5.2e-06	1.28e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—MAPK8—atopic dermatitis	5.2e-06	1.28e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—MAPK8—atopic dermatitis	5.17e-06	1.28e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL5—atopic dermatitis	5.17e-06	1.28e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—atopic dermatitis	5.15e-06	1.27e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD4—atopic dermatitis	5.11e-06	1.26e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL2—atopic dermatitis	5.04e-06	1.24e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL2—atopic dermatitis	4.97e-06	1.23e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CXCL8—atopic dermatitis	4.94e-06	1.22e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—atopic dermatitis	4.92e-06	1.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1B—atopic dermatitis	4.9e-06	1.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—CD4—atopic dermatitis	4.89e-06	1.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL2—atopic dermatitis	4.88e-06	1.2e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NGF—atopic dermatitis	4.79e-06	1.18e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—atopic dermatitis	4.76e-06	1.17e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—atopic dermatitis	4.75e-06	1.17e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—atopic dermatitis	4.74e-06	1.17e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1B—atopic dermatitis	4.72e-06	1.16e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—CD4—atopic dermatitis	4.72e-06	1.16e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL2—atopic dermatitis	4.72e-06	1.16e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL2—atopic dermatitis	4.7e-06	1.16e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IFNG—atopic dermatitis	4.68e-06	1.16e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCR5—atopic dermatitis	4.66e-06	1.15e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CXCL8—atopic dermatitis	4.65e-06	1.15e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MAPK8—atopic dermatitis	4.64e-06	1.15e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NFKBIA—atopic dermatitis	4.63e-06	1.14e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—atopic dermatitis	4.58e-06	1.13e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MAPK8—atopic dermatitis	4.58e-06	1.13e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD4—atopic dermatitis	4.52e-06	1.12e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—atopic dermatitis	4.52e-06	1.12e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—MAPK8—atopic dermatitis	4.49e-06	1.11e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NFKBIA—atopic dermatitis	4.46e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL2—atopic dermatitis	4.44e-06	1.1e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—atopic dermatitis	4.37e-06	1.08e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MAPK8—atopic dermatitis	4.34e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—MAPK8—atopic dermatitis	4.33e-06	1.07e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—atopic dermatitis	4.29e-06	1.06e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—atopic dermatitis	4.2e-06	1.04e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1B—atopic dermatitis	4.18e-06	1.03e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—CD4—atopic dermatitis	4.18e-06	1.03e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—atopic dermatitis	4.16e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK8—atopic dermatitis	4.09e-06	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CXCL8—atopic dermatitis	4.06e-06	1e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—atopic dermatitis	4.04e-06	9.96e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL8—atopic dermatitis	3.96e-06	9.78e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NFKBIA—atopic dermatitis	3.95e-06	9.74e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—atopic dermatitis	3.88e-06	9.58e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—atopic dermatitis	3.88e-06	9.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—atopic dermatitis	3.86e-06	9.53e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK8—atopic dermatitis	3.83e-06	9.45e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—atopic dermatitis	3.82e-06	9.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—atopic dermatitis	3.8e-06	9.37e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—atopic dermatitis	3.79e-06	9.35e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—atopic dermatitis	3.78e-06	9.32e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—atopic dermatitis	3.72e-06	9.19e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—atopic dermatitis	3.71e-06	9.15e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—atopic dermatitis	3.65e-06	9.01e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—atopic dermatitis	3.63e-06	8.96e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—atopic dermatitis	3.61e-06	8.91e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—atopic dermatitis	3.59e-06	8.85e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK8—atopic dermatitis	3.57e-06	8.81e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—atopic dermatitis	3.53e-06	8.71e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK8—atopic dermatitis	3.49e-06	8.6e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—atopic dermatitis	3.45e-06	8.52e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—atopic dermatitis	3.45e-06	8.52e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—atopic dermatitis	3.44e-06	8.5e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK8—atopic dermatitis	3.41e-06	8.42e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—atopic dermatitis	3.37e-06	8.32e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK8—atopic dermatitis	3.36e-06	8.29e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—atopic dermatitis	3.36e-06	8.28e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK8—atopic dermatitis	3.34e-06	8.25e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—atopic dermatitis	3.33e-06	8.22e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—atopic dermatitis	3.32e-06	8.19e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—atopic dermatitis	3.3e-06	8.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—atopic dermatitis	3.3e-06	8.14e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—atopic dermatitis	3.26e-06	8.04e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—atopic dermatitis	3.18e-06	7.85e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—atopic dermatitis	3.18e-06	7.84e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARA—atopic dermatitis	3.16e-06	7.79e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—atopic dermatitis	3.15e-06	7.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—atopic dermatitis	3.14e-06	7.74e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—atopic dermatitis	3.06e-06	7.56e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—atopic dermatitis	3.05e-06	7.52e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—atopic dermatitis	3.04e-06	7.5e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—atopic dermatitis	2.96e-06	7.31e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—atopic dermatitis	2.92e-06	7.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK8—atopic dermatitis	2.9e-06	7.16e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—atopic dermatitis	2.87e-06	7.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—atopic dermatitis	2.82e-06	6.95e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK8—atopic dermatitis	2.8e-06	6.9e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—atopic dermatitis	2.77e-06	6.84e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—atopic dermatitis	2.76e-06	6.82e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—atopic dermatitis	2.69e-06	6.64e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—atopic dermatitis	2.65e-06	6.53e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—atopic dermatitis	2.61e-06	6.44e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—atopic dermatitis	2.55e-06	6.29e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK8—atopic dermatitis	2.48e-06	6.11e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—atopic dermatitis	2.45e-06	6.04e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—atopic dermatitis	2.28e-06	5.63e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—atopic dermatitis	2.26e-06	5.57e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—atopic dermatitis	2.23e-06	5.49e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—atopic dermatitis	2.18e-06	5.38e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—atopic dermatitis	2.15e-06	5.29e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—atopic dermatitis	2.13e-06	5.27e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARA—atopic dermatitis	1.95e-06	4.8e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—atopic dermatitis	1.85e-06	4.57e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—atopic dermatitis	1.79e-06	4.41e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—atopic dermatitis	1.58e-06	3.9e-06	CbGpPWpGaD
